Carboplatin therapy for advanced prostate cancer with genetic mutations
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding carboplatin (a chemotherapy drug) to hormone therapy helps men with advanced prostate cancer that has either a BRCA gene mutation or specific neuroendocrine features. The goal is to improve survival and disease control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with prostate cancer that has spread to bones or distant lymph nodes
- Either carry a BRCA gene mutation OR have prostate cancer with neuroendocrine differentiation (specific cell changes visible under a microscope)
- Have recently started hormone therapy (ADT and ARPI drugs) but not for more than 3 months before entering the trial
- Never had chemotherapy for prostate cancer before, and no prior carboplatin or platinum-based drugs
- Good overall health (ECOG performance status 0–1, or 2 if caused by cancer), with normal or near-normal blood counts and kidney/liver function
- Age 18–80 years old and able to take pills by mouth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
This trial tests QLC5508, a new targeted drug for men with metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread and stopped responding to hormone therapy). The drug is designed to work in patients whose cancer has progressed despite prior hormone-based treatments.
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.